56148
doi
10.5281/zenodo.56148
oai:zenodo.org:56148
Bloemenkamp, Kitty
Leiden University Medical Center
von Dadelszen, Peter
St George’s, University of London
de Groot, Christianne
VU Medisch Centrum
de Laat, Monique
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Mol, Ben Willem
the University of Adelaide
Porath, Martina
Maxima Medical Center, Veldhoven
van der Post, Joris
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
van Wassenaer, Aleid
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction)
Ganzevoort, Wessel
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Sildenafil
intrauterine growth restrictions (IUGR)
fetal growth restriction (FGR)
Adverse neonatal outcome
randomised controlled trial (RCT)
Phosphodiesterase 5 Inhibitors
<p>Severe, early-onset fetal growth restriction (FGR) due to placental insufficiency is<br />
associated with a high risk of perinatal morbidity with long-lasting sequelae and mortality. Placental insufficiency is the result of abnormal formation and function of the placenta (placentation) with inadequate remodelling of the maternal spiral (uteroplacental) arteries. There is currently no therapy available with demonstrated effectiveness. Evidence suggests Sildenafil citrate improves uteroplacental blood flow, growth, and meaningful outcomes. An objective of the study is to evaluate the effectiveness of sildenafil (versus placebo) in achieving healthy perinatal survival.</p>
Zenodo
2016-05-18
info:eu-repo/semantics/researchProposal
637181
1579533270.397259
590708
md5:f296ff79868ce32364afc3a1281a27b0
https://zenodo.org/records/56148/files/Onderzoeksprotocol_versie_7_20_december_2015.pdf
public
isVersionOf
doi